Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Ensysce Biosciences, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −1 vs. Q4 2025
- Shares held
- 487.0K
- +21.1K (+4.5%) vs. Q4 2025
- Total value
- $261.5K
- −$165.9K (−38.8%) vs. Q4 2025
- New holders
- 6
- 5 more added
- Sold out
- 7
- 0 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $810.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 149,711 | $80.6K | 0.00% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 86,666 | $46.7K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 73,880 | $39.8K | 0.00% | +51,790+234.4% | Added |
| Citadel Advisors LLC | 57,363 | $30.9K | 0.00% | +57,363 | New |
| XTX Topco Ltd | 24,363 | $13.1K | 0.00% | +24,363 | New |
| Vanguard Fiduciary Trust Co | 23,854 | $12.9K | 0.00% | +23,854 | New |
| Jane Street Group, LLC | 13,570 | $7.31K | 0.00% | +13,570 | New |
| Tru Independence Asset Management 2, LLC | 13,000 | $7.00K | 0.00% | +1,000+8.3% | Added |
| Virtu Financial LLC | 13,313 | $7.00K | 0.00% | +13,313 | New |
| Vanguard Capital Management LLC | 12,854 | $6.93K | 0.00% | +12,854 | New |
| UBS Group AG | 8,791 | $4.73K | 0.00% | +8,691+8,691.0% | Added |
| Tower Research Capital LLC (TRC) | 6,094 | $3.28K | 0.00% | +775+14.6% | Added |
| FNY Investment Advisers, LLC | 3,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 486 | $262 | 0.00% | +65+15.4% | Added |
| BlackRock, Inc. | 65 | $35 | 0.00% | 00.0% | Unchanged |
| DRW Securities, LLC | 0 | $0 | 0.00% | −98,481−100.0% | Sold out |
| Financial Plan, Inc. | 0 | $0 | 0.00% | −24,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −24,491−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −21,605−100.0% | Sold out |
| Williams & Novak, LLC | 0 | $0 | 0.00% | −17,850−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −72−100.0% | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −41−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |